<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Neuroinflammation - Latest articles</title>
		<link>http://www.jneuroinflammation.com</link>
		<description>The latest articles from Journal of Neuroinflammation (ISSN 1742-2094) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/43"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/42"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/41"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/40"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/39"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/38"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/37"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/36"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/35"/>			    
            
				    <rdf:li rdf:resource="http://www.jneuroinflammation.com/content/5/1/34"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/43">
            
            <title>Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway</title>
			<description>Background:
Microglia are macrophage-like cells that constantly sense the microenvironment within the central nervous system (CNS).  In the event of neuronal stress or injury, microglial cells rapidly react and change their phenotype. This response may lead to a deleterious type of microglial activation, which is often associated with neuroinflammation and neurotoxicity in several neuropathological conditions. We investigated the molecular mechanisms underlying triggering of microglial activation by necrotic neuronal damage.
Methods:
Primary cultures of microglia were used to study the effect of necrotic neurons on microglial inflammatory responses and toxicity towards cerebellar granule neurons (CGN). The mouse hippocampal cell line, HT22, was used in this study as the main source of necrotic neurons to stimulate microglia. To identify the signal transduction pathways activated in microglia, primary microglial cultures were obtained from mice deficient in Toll-like receptor (TLR) -2, -4, or in the TLR adapter protein MyD88. 
Results:
Necrotic neurons, but not other necrotic cell types, induced microglial activation which was characterized by up-regulation of: i) MHC class II; ii) co-stimulatory molecules, i.e. CD40 and CD24; iii) beta-2 integrin CD11b; iii) pro-inflammatory cytokines, i.e. interleukin 6 (IL-6), IL-12p40 and tumor-necrosis factor (TNF); iv) pro-inflammatory enzymes such as nitric oxide synthase (iNOS, type II NOS), indoleamine 2,3-dioxygenase (IDO) and cyclooxygenase-2 (COX-2) and increased microglial motility. Moreover, microglia-conditioned medium (MCM) obtained from cultures of activated microglia showed increased neurotoxicity mediated through the N-methyl-D-aspartate receptor (NMDAR). The activation of microglia by necrotic neurons was shown to be dependent on the TLR-associated adapter molecule myeloid differentiation primary response gene (MyD88). Furthermore, MyD88 mediated enhanced neurotoxicity by activated microglia through up-regulation of the expression and activity of glutaminase, an enzyme that produces glutamate, which is an NMDAR agonist. 
Conclusions:
These results show that necrotic neurons activate in microglia a MyD88-dependent pathway responsible for a pro-inflammatory response that also leads to increased neurotoxic activity through induction of glutaminase. This finding contributes to better understanding the mechanisms causing increased neuroinflammation and microglial neurotoxicity in a neurodegenerative environment.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/43</link>
			
			 	<dc:creator>Teresa F Pais, Catarina Figueiredo, Rui Peixoto, Maria H Braz and Sukalyan Chatterjee</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:43</dc:source>
			<dc:date>2008-10-09</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-43</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>43</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-09</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/42">
            
            <title>Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice</title>
			<description>Background:
New pre-clinical trials in AD mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse responses that occurred during the clinical trials with AN-1792 vaccine formulation.  Recently, we have pursued an alternative immunization strategy that replaces QS21 the Th1 type adjuvant used in the AN-1792 clinical trial with a molecular adjuvant, mannan that can promote a Th2-polarized immune response through interactions with mannose-binding and CD35/CD21 receptors of the innate immune system.  Previously we established that immunization of wild-type mice with mannan-A-beta-28 conjugate promoted Th2-mediated humoral and cellular immune responses. In the current study, we tested the efficacy of this vaccine configuration in amyloid precursor protein (APP) transgenic mice (Tg2576).  
Methods:
Mannan was purified, activated and chemically conjugated to A-beta-28 peptide.  Humoral immune responses induced by the immunization of mice with mannan- A-beta-28 conjugate were analyzed using a standard ELISA.  A-beta-42 and A-beta-40 amyloid burden, cerebral amyloid angiopathy (CAA), astrocytosis, and microgliosis in the brain of immunized and control mice were detected using immunohistochemistry. Additionally, cored plaques and cerebral vascular microhemorrhages in the brains of vaccinated mice were detected by standard histochemistry.  
Results:
Immunizations with low doses of mannan-A-beta-28 induced potent and long-lasting anti-A-beta humoral responses in Tg2576 mice.  Even 11 months after the last injection, the immunized mice were still producing low levels of anti-A-beta antibodies, predominantly of the IgG1 isotype, indicative of a Th2 immune response. Vaccination with mannan-A-beta-28 prevented A-beta plaque deposition, but unexpectedly increased the level of microhemorrhages in the brains of aged immunized mice compared to two groups of control animals of the same age either injected with molecular adjuvant fused with an irrelevant antigen, BSA (mannan-BSA) or non-immunized mice.  Of note, mice immunized with mannan- A-beta-28 showed a trend toward elevated levels of CAA in the neocortex and in the leptomeninges compared to that in mice of both control groups.       
Conclusions:
Mannan conjugated to A-beta-28 provided sufficient adjuvant activity to induce potent anti-A-beta antibodies in APP transgenic mice, which have been shown to be hyporesponsive to immunization with A-beta self-antigen.  However, in old Tg2576 mice there were increased levels of cerebral microhemorrhages in mannan- A-beta-28 immunized mice.  This effect was likely unrelated to the anti-mannan antibodies induced by the immunoconjugate, because control mice immunized with mannan-BSA also induced antibodies specific to mannan, but did not have increased levels of cerebral microhemorrhages compared with non-immunized mice. Whether these anti-mannan antibodies increased the permeability of the blood brain barrier thus allowing elevated levels of anti-A-beta antibodies entry into cerebral perivascular or brain parenchymal spaces and contributed to the increased incidence of microhemorrhages remains to be investigated in the future studies.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/42</link>
			
			 	<dc:creator>Irina Petrushina, Anahit Ghochikyan, Mikayel Mkrtichyan, Grigor Mamikonyan, Nina Movsesyan, Rodmehr Ajdari, Vitaly Vasilevko, Adrine Karapetyan, Andrew Lees, Michael G Agadjanyan and David H Cribbs</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:42</dc:source>
			<dc:date>2008-09-29</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-42</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>42</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/41">
            
            <title>Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression</title>
			<description>Background:
It is well known that most neurodegenerative diseases are associated with microglia-mediated inflammation.  Our previous research demonstrates that the CD40 signaling is critically involved in microglia-related immune responses in the brain.  For example, it is well known that the activation of the signal transducer and activator of transcription (STAT) signaling pathway plays a central role in interferon-gamma (IFN-gamma)-induced microglial CD40 expression.  We and others have previously reported that microglial CD40 expression is significantly induced by IFN-gamma and amyloid-beta (Abeta) peptide.  Recent studies have shown that certain flavonoids possess anti-inflammatory and neuroprotective properties distinct from their well-known anti-oxidant effects.  In particular, flavonoids, apigenin and luteolin have been found to be effective CD40 immunomodulators.
Methods:
Cultured microglia, both N9 and primary derived lines, were treated with flavonoids in the presence of IFN-gamma and/or CD40 ligation to assess any anti-inflammatory effects and/or mechanisms.  CD40 expression on microglia was analyzed by fluorescence activated cell sorting (FACS).  Anti-inflammatory effects and mechanisms were confirmed by ELISA for interlekin-6 (IL-6) and TNF-alpha, lactate dehydrogenase (LDH) assay, and STAT1 Western blotting.       
Results:
Apigenin and luteolin concentration-dependently suppressed IFN-gamma-induced CD40 expression.  Apigenin and luteolin also suppressed microglial TNF-alpha and IL-6 production stimulated by IFN-gamma challenge in the presence of CD40 ligation.  In addition, apigenin and luteolin markedly inhibited IFN-gamma-induced phosphorylation of STAT1 with little impact on cell survival.
Conclusion:
Our findings provide further support for apigenin and luteolin's anti-inflammatory effects and suggest that these flavonoids may have neuroprotective/disease-modifying properties in various neurodegenerative disorders, including Alzheimer's disease (AD).</description>
			<link>http://www.jneuroinflammation.com/content/5/1/41</link>
			
			 	<dc:creator>Kavon Rezai-Zadeh, Jared Ehrhart, Yun Bai, Paul R Sanberg, Paula C Bickford, Jun Tan and R. Douglas Shytle</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:41</dc:source>
			<dc:date>2008-09-25</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-41</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>41</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/40">
            
            <title>Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis</title>
			<description>Background:
The long latent stage seen in syphilis, followed by chronic central nervous system infection and inflammation, can be explained by the persistence of atypical cystic and granular forms of Treponema pallidum. We investigated whether a similar situation may occur in Lyme neuroborreliosis.MethodAtypical forms of Borrelia burgdorferi spirochetes were induced exposing cultures of Borrelia burgdorferi (strains B31 and ADB1) to such unfavorable conditions as osmotic and heat shock, and exposure to the binding agents Thioflavin S and Congo red. We also analyzed whether these forms may be induced in vitro, following infection of primary chicken and rat neurons, as well as rat and human astrocytes. We further analyzed whether atypical forms similar to those induced in vitro may also occur in vivo, in brains of three patients with Lyme neuroborreliosis. We used immunohistochemical methods to detect evidence of neuroinflammation in the form of reactive microglia and astrocytes.
Results:
Under these conditions we observed atypical cystic, rolled and granular forms of these spirochetes. We characterized these abnormal forms by histochemical, immunohistochemical, dark field and atomic force microscopy (AFM) methods. The atypical and cystic forms found in the brains of three patients with neuropathologically confirmed Lyme neuroborreliosis were identical to those induced in vitro. We also observed nuclear fragmentation of the infected astrocytes using the TUNEL method. Abundant HLA-DR positive microglia and GFAP positive reactive astrocytes were present in the cerebral cortex.
Conclusion:
The results indicate that atypical extra- and intracellular pleomorphic and cystic forms of Borrelia burgdorferi and local neuroinflammation occur in the brain in chronic Lyme neuroborreliosis. The persistence of these more resistant spirochete forms, and their intracellular location in neurons and glial cells, may explain the long latent stage and persistence of Borrelia infection. The results also suggest that Borrelia burgdorferi may induce cellular dysfunction and apoptosis. The detection and recognition of atypical, cystic and granular forms in infected tissues is essential for the diagnosis and the treatment as they can occur in the absence of the typical spiral Borrelia form.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/40</link>
			
			 	<dc:creator>Judith Miklossy, Sandor Kasas, Anne D Zurn, Sherman McCall, Sheng Yu and Patrick L McGeer</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:40</dc:source>
			<dc:date>2008-09-25</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-40</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>40</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/39">
            
            <title>Corticosteroids reverse cytokine-induced block of survival and differentiation of oligodendrocyte progenitor cells from rats</title>
			<description>Background:
Periventricular leukomalacia (PVL) is a frequent complication of preterm delivery. Proinflammatory cytokines, such as interferon-&#947; (IFN-&#947;) and tumor necrosis factor &#945; (TNF-&#945;) released from astrocytes and microglia activated by infection or ischemia have previously been shown to impair survival and maturation of oligodendrocyte progenitors and could thus be considered as potential factors contributing to the generation of this disease. The first goal of the present study was to investigate whether exposure of oligodendrocyte precursors to these cytokines arrests the maturation of ion currents in parallel to its effects on myelin proteins and morphological maturation. Secondly, in the search for agents, that can protect differentiating oligodendrocyte precursor cells from cytokine-induced damage we investigated effects of coapplications of corticosteroids with proinflammatory cytokines on the subsequent survival and differentiation of oligodendrocyte progenitor cells.
Methods:
To exclude influences from factors released from other cell types purified cultures of oligodendrocyte precursors were exposed to cytokines and/or steroids and allowed to differentiate for further 6 days in culture. Changes in membrane surface were investigated with capacitance recordings and Scanning Ion Conductance Microscopy. Na+- and K+- currents were investigated using whole cell patch clamp recordings. The expression of myelin specific proteins was investigated using western blots and the precursor cells were identified using immunostaining with A2B5 antibodies.
Results:
Surviving IFN-&#947; and TNF-&#945; treated cells continued to maintain voltage-activated Na+- and K+ currents characteristic for the immature cells after 6 days in differentiation medium. Corticosterone, dihydrocorticosterone and, most prominently dexamethasone, counteracted the deleterious effects of IFN-&#947; and TNF-&#945; on cell survival, A2B5-immunostaining and expression of myelin basic protein. The most potent corticosteroid tested, dexamethasone, was shown to counteract cytokine effects on membrane surface extension and capacitance. Furthermore, coapplication of dexamethasone blocked the cytokine-induced downregulation of the inwardly rectifying potassium current in 80% of the precursor cells and restored the cytokine-blocked down-regulation of the voltage activated Na+- and K+ currents during subsequent differentiation.
Conclusion:
Our results show that treatment of oligodendrocyte precursors with the inflammatory cytokines TNF-&#945; and IFN-&#947; block the differentiation of oligodendrocyte precursors at the level of the differentiation of the voltage-gated ion currents. Co-treatment with corticosteroids at the time of cytokine application restores to a considerable extent survival and differentiation of oligodendrocytes at the level of morphological, myelin protein as well as ion current maturation suggesting the option for a functional restoration of cytokine-damaged immature oligodendrocytes.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/39</link>
			
			 	<dc:creator>Stefan A Mann, Beatrix Versmold, Romy Marx, Sabine Stahlhofen, Irmgard D Dietzel, Rolf Heumann and Richard Berger</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:39</dc:source>
			<dc:date>2008-09-22</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-39</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>39</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/38">
            
            <title>Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism</title>
			<description>Background:
Septic encephalopathy is a severe brain dysfunction caused by systemic inflammation in the absence of direct brain infection. Changes in cerebral blood flow, release of inflammatory molecules and metabolic alterations contribute to neuronal dysfunction and cell death.
Methods:
To investigate the relation of electrophysiological, metabolic and morphological changes caused by SE, we simultaneously assessed systemic circulation, regional cerebral blood flow and cortical electroencephalography in rats exposed to bacterial lipopolysaccharide. Additionally, cerebral glucose uptake, astro- and microglial activation as well as changes of inflammatory gene transcription were examined by small animal PET using [18F]FDG, immunohistochemistry, and real time PCR.
Results:
While the systemic hemodynamic did not change significantly, regional cerebral blood flow was decreased in the cortex paralleled by a decrease of alpha activity of the electroencephalography. Cerebral glucose uptake was reduced in all analyzed neocortical areas, but preserved in the caudate nucleus, the hippocampus and the thalamus. Sepsis enhanced the transcription of several pro- and anti-inflammatory cytokines and chemokines including tumor necrosis factor alpha, interleukin-1 beta, transforming growth factor beta, and monocot chemoattractant protein 1 in the cerebrum. Regional analysis of different brain regions revealed an increase in ED1-positive microglia in the cortex, while total and neuronal cell counts decreased in the cortex and the hippocampus.
Conclusion:
Together, the present study highlights the complexity of sepsis induced early impairment of neuronal metabolism and activity. Since our model uses techniques that determine parameters relevant to the clinical setting, it might be a useful tool to develop brain specific therapeutic strategies for human septic encephalopathy.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/38</link>
			
			 	<dc:creator>Alexander Semmler, Sven Hermann, Florian Mormann, Marc Weberpals, Stephan A Paxian, Thorsten Okulla, Michael Sch&#228;fers, Markus P Kummer, Thomas Klockgether and Michael T Heneka</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:38</dc:source>
			<dc:date>2008-09-15</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-38</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>38</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/37">
            
            <title>Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation</title>
			<description>Background:
Alzheimer's disease (AD) is characterized by extensive loss of neurons in the brain of AD patients. Intracellular accumulation of beta-amyloid peptide (A&#946;) has also shown to occur in AD. Neuro-inflammation has been known to play a role in the pathogenesis of AD.
Methods:
In this study, we investigated neuro-inflammation and amyloidogenesis and memory impairment following the systemic inflammation generated by lipopolysaccharide (LPS) using immunohistochemistry, ELISA, behavioral tests and Western blotting.
Results:
Intraperitoneal injection of LPS, (250 &#956;g/kg) induced memory impairment determined by passive avoidance and water maze tests in mice. Repeated injection of LPS (250 &#956;g/kg, 3 or 7 times) resulted in an accumulation of A&#946;1&#8211;42 in the hippocampus and cerebralcortex of mice brains through increased &#946;- and &#947;-secretase activities accompanied with the increased expression of amyloid precursor protein (APP), 99-residue carboxy-terminal fragment of APP (C99) and generation of A&#946;1&#8211;42 as well as activation of astrocytes in vivo. 3 weeks of pretreatment of sulindac sulfide (3.75 and 7.5 mg/kg, orally), an anti-inflammatory agent, suppressed the LPS-induced amyloidogenesis, memory dysfunction as well as neuronal cell death in vivo. Sulindac sulfide (12.5&#8211;50 &#956;M) also suppressed LPS (1 &#956;g/ml)-induced amyloidogenesis in cultured neurons and astrocytes in vitro.
Conclusion:
This study suggests that neuro-inflammatory reaction could contribute to AD pathology, and anti-inflammatory agent could be useful for the prevention of AD.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/37</link>
			
			 	<dc:creator>Jae Woong Lee, Yong Kyung Lee, Dong Yeon Yuk, Dong Young Choi, Sang Bae Ban, Ki Wan Oh and Jin Tae Hong</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:37</dc:source>
			<dc:date>2008-08-29</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-37</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>37</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/36">
            
            <title>Association of alleles carried at TNFA -850 and BAT1 -22 with Alzheimer's disease</title>
			<description>Background:
Inflammatory changes are a prominent feature of brains affected by Alzheimer's disease (AD). Activated glial cells release inflammatory cytokines which modulate the neurodegenerative process. These cytokines are encoded by genes representing several interleukins and TNFA, which are associated with AD. The gene coding for HLA-B associated transcript 1 (BAT1) lies adjacent to TNFA in the central major histocompatibility complex (MHC). BAT1, a member of the DEAD-box family of RNA helicases, appears to regulate the production of inflammatory cytokines associated with AD pathology. In the current study TNFA and BAT1 promoter polymorphisms were analysed in AD and control cases and BAT1 mRNA levels were investigated in brain tissue from AD and control cases.
Methods:
Genotyping was performed for polymorphisms at positions -850 and -308 in the proximal promoter of TNFA and position -22 in the promoter of BAT1. These were investigated singly or in haplotypic association in a cohort of Australian AD patients with AD stratified on the basis of their APOE &#949;4 genotype. Semi-quantitative RT-PCR was also performed for BAT1 from RNA isolated from brain tissue from AD and control cases.
Results:
APOE &#949;4 was associated with an independent increase in risk for AD in individuals with TNFA -850*2, while carriage of BAT1 -22*2 reduced the risk for AD, independent of APOE &#949;4 genotype. Semi-quantitative mRNA analysis in human brain tissue showed elevated levels of BAT1 mRNA in frontal cortex of AD cases.
Conclusion:
These findings lend support to the application of TNFA and BAT1 polymorphisms in early diagnosis or risk assessment strategies for AD and suggest a potential role for BAT1 in the regulation of inflammatory reactions in AD pathology.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/36</link>
			
			 	<dc:creator>Anastazija Gnjec, Katarzyna J D'Costa, Simon M Laws, Ross Hedley, Kelvin Balakrishnan, Kevin Taddei, Georgia Martins, Athena Paton, Giuseppe Verdile, Samuel E Gandy, G Anthony Broe, William S Brooks, Hayley Bennett, Olivier Piguet, Patricia Price, Judith Miklossy, Joachim Hallmayer, Patrick L McGeer and Ralph N Martins</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:36</dc:source>
			<dc:date>2008-08-20</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-36</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>36</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/35">
            
            <title>MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult</title>
			<description>Background:
An endotoxin insult mimics a severe peripheral infection and recent evidence suggests that a single exposure can cause long-term cognitive deficits. A peripheral injection of LPS results in production of pro-inflammatory cytokines, such as IL-1&#946; and TNF-&#945;, in the brain and periphery and these cytokines mediate many effects of the acute phase response including activation of the HPA axis. The chemokine MCP-1 is highly expressed during endotoxemia and although much is known about the importance of MCP-1 in peripheral inflammatory responses to LPS, information about MCP-1 and CNS responses to peripheral LPS is lacking.
Methods:
C57Bl/6 mice were administered LPS by intraperitoneal (i.p.) injection, serum and brains were collected at several time points, and the time course of MCP-1 protein up-regulation was measured. To examine the role of MCP-1 in activation of the brain during acute systemic inflammation, we injected MCP-1 knockout (MCP-1-/-) or control C57Bl/6 (MCP-1+/+) mice with LPS i.p. and measured the levels of selected cytokines and chemokines in serum and brain extracts 6 hours later. Activated microglia were examined by CD45 immunohistochemistry, and serum corticosterone and ACTH levels were measured by enzyme immunoassay.
Results:
We report that LPS injection induces a robust increase in MCP-1 protein levels in serum and brain, with peak brain levels reached at 6 hrs after LPS administration. MCP-1-/- mice injected with LPS showed higher levels of serum IL-1&#946; and TNF-&#945; compared to LPS-treated MCP-1+/+ mice. In contrast, these MCP-1-/- mice showed significantly lower inductions of brain pro-inflammatory cytokines and chemokines, fewer activated microglia, and a reduction in serum corticosterone levels.
Conclusion:
MCP-1-/- mice have decreased brain inflammation after a peripheral LPS insult, despite an exaggerated peripheral response. These data demonstrate an important role for MCP-1 in regulation of brain inflammation after peripheral endotoxemia.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/35</link>
			
			 	<dc:creator>Wendy L Thompson, William J Karpus and Linda J Van Eldik</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:35</dc:source>
			<dc:date>2008-08-15</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-35</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>35</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.jneuroinflammation.com/content/5/1/34">
            
            <title>Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat</title>
			<description>Background:
Hypoxia-ischemia (H-I) can produce widespread neurodegeneration and deep cerebral white matter injury in the neonate. Resident microglia and invading leukocytes promote lesion progression by releasing reactive oxygen species, proteases and other pro-inflammatory mediators. After injury, expression of the gelatin-degrading matrix metalloproteinases (MMPs), MMP-2 and MMP-9, are thought to result in the proteolysis of extracellular matrix (ECM), activation of cytokines/chemokines, and the loss of vascular integrity. Thus, therapies targeting ECM degradation and progressive neuroinflammation may be beneficial in reducing H-I &#8211; induced neuropathy. Minocycline has MMP-inhibitory properties and is both anti-inflammatory and neuroprotective. AG3340 (prinomastat) is an MMP inhibitor with high selectivity for the gelatinases. The purpose of this study was to determine whether these compounds could limit H-I &#8211; induced injury when administered at a delayed time point.
Methods:
Sprague-Dawley rats were exposed to H-I at postnatal day 7 (P7), consisting of unilateral carotid artery ligation followed by 90 min exposure to 8% O2. Minocycline, AG3340, or vehicle were administered once daily for 6 days, beginning 24 hours after insult. Animals were sacrificed at P14 for neurohistological assessments. Immunohistochemistry was performed to determine the degree of reactive astrogliosis and immune cell activation/recruitment. Neural injury was detected using the Fluoro-Jade stain, a marker that identifies degenerating cells.
Results:
CD11b and glial fibrillary acidic protein (GFAP) immunopositive cells increased in ipsilateral cortex after treatment with vehicle alone, demonstrating microglia/macrophage recruitment and reactive astrogliosis, respectively. Fluoro-Jade staining was markedly increased throughout the fronto-parietal cortex, striatum and hippocampus. Treatment with minocycline or AG3340 inhibited microglia/macrophage recruitment, attenuated astrogliosis and reduced Fluoro-Jade staining when compared to vehicle alone.
Conclusion:
The selective gelatinase inhibitor AG3340 showed equal efficacy in reducing neural injury and dampening neuroinflammation when compared to the anti-inflammatory compound minocycline. Thus, MMP-2 and MMP-9 may be viable therapeutic targets to treat neonatal brain injury.</description>
			<link>http://www.jneuroinflammation.com/content/5/1/34</link>
			
			 	<dc:creator>Christopher C Leonardo, Autumn K Eakin, Joanne M Ajmo, Lisa A Collier, Keith R Pennypacker, Alex Y Strongin and Paul E Gottschall</dc:creator>
			
			<dc:source>Journal of Neuroinflammation 2008, 5:34</dc:source>
			<dc:date>2008-08-11</dc:date>
			<dc:identifier>doi:10.1186/1742-2094-5-34</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Neuroinflammation</prism:publicationName>
					
			
							
					<prism:issn>1742-2094</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>34</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
